

Minute of the Annual General Meeting of Shareholders 2025
Bangkok Genomics Innovation Public Company Limited

Date, Time and Place

The meeting was held on April 28, 2025, at 10:30 hours, via Electronic Meeting.

Dr.Thosaporn Sirisumphand, Chairman of the Board, acting as the Chairman of the Meeting (“Chairman”). The Chairman welcomed the shareholders, proxies, directors, executives, and all attendees who attended the meeting and informed the Meeting that there were 38 shareholders and proxies holding altogether 436,244,100 shares, representing 72.7074% of the total paid-up shares of the Company, amounting to 600,000,000 shares, exceeding one-third of all outstanding shares. A quorum was thereby constituted pursuant to the Articles of Association of the Company. The Chairman then declared the Meeting open.

Before proceeding to the meeting agenda, the Chairman assigned Ms.Achiraya Rabiabnaveenurak to act as the master of ceremonies and meeting moderator. The moderator then introduced the directors, executives, and auditors as follows:

Directors attending the meeting in the conference room

1.	Dr. Thosaporn	Sirisumphand	Chairman of the Board and Independent Director
2.	Mr. Goanpot	Asvinvichit	Chairman of the Executive Committee
3.	Mr. Preecha	Laohapongchana	Executive Committee
4.	Mr. Vichate	Tantiwanich	Chairman of the Audit Committee and Independent Director
5.	Dr. Vichya	Kreangam	Audit Committee and Independent Director
6.	Dr. Saowalak	Dansakul	Executive Committee and Chief Executive Officer
7.	Mr. Xiaohan	Wang	Executive Committee and Deputy Chief Executive Officer
8.	Mr. Sujie	Cao	Executive Committee

Directors attending the meeting via the electronic channel

9.	Mr. Jedsada	Chokdamsongsuk	Audit Committee and Independent Director
10.	Dr. Ning	Li	Director
11.	Mr. Zongze	Wu	Director

All 11 directors out of a total of 11 were present at the meeting, representing 100% of the Board of Directors.

Management attending the meeting in the conference room

1.	Mr. Kittikun	Rodrangnok	Chief Financial Officer
----	--------------	------------	-------------------------

Auditors attending the meeting via the electronic channel

1.	Mr. Chaikakorn	Aunpitipongsa	Managing Director, Dr.Virach and Associates
2.	Mr. Tirawot	Laonapakul	Senior Audit Manager, Dr.Virach and Associates

Other

1.	Ms. Nuttinee	Kittisorayut	Company's secretary
----	--------------	--------------	---------------------

Additionally, IR Network Co., Ltd., a public relations consulting firm, was present at the meeting. Mr. Supotch Onlamoon was responsible for verifying shareholder registrations and counting the votes.

Before proceeding to consider each agenda item of the meeting, the Chairman invited Ms.Achiraya Rabiabnaveenurak to explain the meeting procedures, the voting rules, and the details of each agenda item to the attendees. The company utilized the online meeting services provided by Affinity Relation Co., Ltd. The key points were as follows:

1. In each agenda item, all participants may vote according to the number of shares they hold or are authorized to represent by proxy, with one share equaling one vote. If any shareholder has a special interest in a particular matter, that shareholder is not entitled to vote on that matter, except in the case of voting for director appointments.
2. Shareholders may not divide their shares by granting proxies to multiple persons in order to split their votes. A shareholder must grant a proxy for the full number of shares held and cannot authorize only a portion, except in the case of a Custodian appointed by a foreign investor as the securities depository and manager, in accordance with Proxy Form C.
3. For those using Proxy Forms B and C, where the grantor has already indicated their voting instructions, the company has recorded the votes according to the grantor's intention.
4. The voting results for each agenda item will be announced immediately after the vote counting for that item is completed.
5. In the event of a tie vote, the Chairman shall cast an additional vote to make the final decision.

For details regarding the voting procedures, the steps are as follows:

1. If any shareholder wishes to vote "Disagree" or "Abstain," please click on the icon of a person on the left side of the screen. The meeting agenda will appear, along with buttons to select "Agree," "Disagree," or "Abstain."
2. Please click on only one of the voting options according to your intention: Agree, Disagree, or Abstain.
3. The time allotted for voting on each agenda item is 1 minute. If voting has not yet closed, shareholders may change their vote at any time until the system closes the voting.
4. The system will display the status of the most recent vote selected.
5. If a shareholder or proxy holder does not press any voting button, the company will consider that person as having voted "Agree" on the agenda item.
6. Once the company announces the closure of the voting system, shareholders or proxy holders will no longer be able to vote on that particular agenda item. The voting status button will indicate that voting is no longer available.
7. The vote count for each agenda item will include only the votes of those who selected "Disagree" or "Abstain." These votes will be subtracted from the total number of votes of the attendees. The remaining votes will be counted as "Agree" votes in favor of the agenda item.
8. After voting is completed, you may click on the person icon again to collapse the left-hand menu and continue participating in the meeting.

The company has recorded the meeting in the form of video media. This process involves the collection, use, and disclosure of personal data, including the voices and video images of all participants, for the purposes of minute-taking, meeting management, and other administrative functions. These actions are conducted in accordance with the Personal Data Protection Act B.E. 2562 (2019) and the laws governing electronic meetings.

Thereafter, the meeting moderator proposed that the meeting proceed to consider the following agenda items.

Agenda 1 Chairman Remarks

The Chairman welcomed the shareholders to the Annual General Meeting, emphasizing the importance of this platform in deliberating and determining the company's strategic direction. He also shared his vision for the future of Thailand's healthcare system, highlighting the need to design health from before birth in order to promote longer and higher-quality lives. The Chairman further addressed the shifting demographics in Thailand, noting the country's rapid transition into an aging society alongside a steadily declining birth rate. This trend underscores the necessity for the company to systematically prepare for and respond to these demographic changes.

In terms of operations, the company continues to focus on advancing genetic innovation, starting with newborn disease screening and the analysis of risks for non-communicable diseases (NCDs) to enable early

prevention and health management. At the same time, the company is conducting feasibility studies on development and investment in research and development of Advanced Therapy Medicinal Products (ATMPs), such as CAR-T cell therapy and Mesenchymal Stem Cell (MSC) therapy, to enhance the effectiveness and accessibility of treatment for chronic and serious illnesses.

Additionally, the company places strong emphasis on longevity and de -aging research, and is currently in discussions and planning collaborations with leading global researchers and institutions. The goal is to develop innovations that enable Thai citizens to live up to 120 years with a high quality of life, in line with the vision of “120 Years of Quality Living.”

Lastly, the Chairman expressed gratitude to all shareholders for their trust and continued support over the past year. He reiterated that shareholders are a key driving force behind the transformation of healthcare and lifestyle models for the Thai population. The company will disclose further relevant information as appropriate, should there be any significant developments or conclusions in the future.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

This agenda was for the meeting's acknowledgement, no voting was required. Therefore, it was concluded that the meeting acknowledged the information from the Chairman regarding the Company's operations and direction.

Agenda 2 **To consider and adopt the minutes of the Annual General Meeting of Shareholders 2024**

The chairman proposed the meeting to consider and certify the Minutes of the Annual General Meeting of Shareholders 2024, held on February 29, 2024, as per the attached details. The Board of Directors has reviewed and confirmed that the minutes are accurate and complete in essential matters.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no objections or requests for amendments to the minutes from any shareholders.

The Chairman therefore requested the meeting to consider and approve the Minutes of the Annual General Meeting of Shareholders 2024.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved and certified the minutes of the 2024 Annual General Meeting of Shareholders held on February 29, 2024, with the following voting results:

Approve	439,153,800	votes	or	99.9999%
Disapprove	0	votes	or	0.0000%
Abstain	100	votes		

Remark: In this agenda item, 4 additional shareholders joined the meeting, resulting in a total of 42 shareholders attending the meeting and eligible to vote prior to the resolution on this agenda item, representing a total of 439,153,900 shares.

Agenda 3 **To acknowledge the reports of board of directors and operating results for the year ended 31 December 2024**

The Chairman informed the meeting that the Board of Directors had prepared the Company's performance report for the fiscal year ended December 31, 2024, and assigned Mr.Kittikun Rodrangnok, Chief Financial Officer, to summarize the operational performance as follows:

For the year 2024, the Company and its subsidiaries demonstrated remarkable growth, with total revenue reaching 345.87 million Baht, an increase of 98.53 million Baht or 40% compared to the previous year—reflecting significant growth across various dimensions.

Operating income increased by 92.20 million Baht or 38%, categorized into two primary segments:

- Service Income which is the Company's main source of income increased from 241.38 million Baht in the previous year to 256.50 million Baht, reflecting 6% growth. This was partly driven by expanded collaborations with fertility clinics, leading to a continued rise in demand for preimplantation genetic testing (PGT-A). Although income from infectious disease testing declined in line with the easing of the COVID-19 situation, other service income grew steadily, resulting in a 15.12 million Baht increase in total service income year on year.
- Product Sales Income increased by 77.08 million Baht, or 1,922% compared to the previous year. This growth was attributed to the expansion of the laboratory products market, including the sale of equipment with monthly reagent orders and specialized reagents for laboratory analysis.

These results highlight the Company's potential to expand into laboratory product distribution, diversify its revenue streams, and efficiently reach niche professional customer segments.

In terms of profitability, the Company had a net profit of 50.16 million Baht, an increase of 18.02 million Baht or 56% from the previous year which is considered strong growth. The net profit margin improved from 13% to 15%, reflecting improved efficiency in cost and revenue management. Earnings per share increased from 0.07 Baht to 0.09 Baht, or 29% growth.

The 2024 performance thus serves as solid evidence of the Company's ability to drive comprehensive growth in revenue, profit, and shareholder returns.

Then, Dr.Saowalak Dansakul, Director and Chief Executive Officer, addressed the meeting on the Company's new genetics-related innovations, summarized as follows:

1. Development of genetic testing services across all life stages

The Company emphasized expanding genetic testing services throughout the life cycle, from From before preconception to elderly years, by utilizing advanced technologies and pricing strategies accessible to Thai citizens. Details by life stage include:

- **Preconception:** Preimplantation Genetic Testing (PGT) for couples undergoing assisted reproductive technologies (e.g., IVF), screening embryos for chromosomal normality to reduce the risk of miscarriage or genetic disorders and enhance successful pregnancy outcomes.
- **Newborn stage:** Newborn Genetic Screening to detect genetic abnormalities such as metabolic disorders at birth, which can be treated or prevented if identified early.
- **Childhood and adolescence:** Analysis of personal traits such as nutrient metabolism, exercise response, and disease risk to support holistic preventive healthcare.
- **Working age:** Genetic testing for major disease risks such as hereditary cancers, including testing of genes like BRCA1 and BRCA2, related to breast, ovarian, colon, pancreatic, and prostate cancers, enabling proper prevention and monitoring.

- **Adulthood and elderly:** Risk assessment for degenerative diseases (e.g., Alzheimer's, cardiovascular disease), and pharmacogenomic analysis to support safer, more precise treatment decisions.

The Company's expert scientific and medical technology team provides ongoing support comparable to public healthcare professionals, with a commitment to promoting preventive and sustainable healthcare, firmly believing that genetic information is key to a healthy and high-quality life.

2. Laboratory service quality certification

The Company places strong emphasis on laboratory standards and has pursued accreditation from relevant authorities to assure service recipients that all genetic testing processes meet international standards.

3. Long-term investment and technology development

The Company continues to enhance business capabilities by investing in genetic decoding tools and technologies, particularly Next Generation Sequencing (NGS) platforms and other advanced genetic analysis tools, to meet future demand and ensure sustainable service expansion.

Additionally, the Company has collaborated with both domestic and international partners to exchange knowledge and jointly develop technologies. The goal is to elevate Thailand's genetic service standards to be globally competitive. The genetic decoding technologies applied by the Company are not only instrumental in medical applications, such as genetic disease screening, hereditary cancer testing, and personalized treatment planning, but can also be applied in agriculture (e.g., developing optimal plant and animal breeds), as well as biological and environmental research.

The Chairman then opened the session for shareholders to ask questions or comments.

On this matter, shareholders raised several questions and provided comments, which can be summarized as follows:

Question 1

Mr.Ekachai Thai-arporn (Shareholder): What is the Company's projected revenue growth target in numerical terms for 2025, and are there any new product launches planned?

Answer 1

Mr.Kittikun Rodrangnok: For the year 2025, the Company targets revenue growth of approximately 20% to 25% compared to the previous year.

Question 2

Mr.Torpong Krongtraiwed (Shareholder): In which countries besides Thailand does the company represent BGI products?

Answer 2

Dr.Saowalak Dansakul: Primarily, the Company serves as a product distributor for BGI exclusively in Thailand. However, for research and development (R&D), the Company collaborates closely with the BGI Group through knowledge exchange and technology transfer processes. Currently, all marketing activities remain focused within Thailand.

Question 3

Mr.Preecha Supkijkarn (Shareholder): What are the Company's strategies for 2025?

Answer 3

Dr.Saowalak Dansakul: In 2025, the Company will focus on expanding genetic services, having started offering cancer diagnostic testing within Thailand. Previously, samples had to be sent abroad, resulting in delays in turnaround time. The core strategy now centers on strengthening domestic capabilities, including the establishment of local pathology laboratories and enhancements in precision and timely treatment planning. In addition, the Company aims to strengthen its technological capabilities to be globally competitive, especially in Next Generation Sequencing (NGS). The Company is also expanding partnerships with experts in NGS solutions to support service delivery across platforms beyond medical applications, with future plans to expand further into the agriculture sector.

There were no further questions or comments from the shareholders.

This agenda was for the meeting's acknowledgement, no voting was required. Therefore, it was concluded that the meeting acknowledged the Company's performance report for the year 2024.

Agenda 4 To consider and approve the financial statements for the year ended 31 December 2024

The Chairman informed the meeting that, pursuant to Section 112 of the Public Limited Companies Act B.E. 2535 (1992) (including its amendments) ("the Public Limited Companies Act") and Article 55 of the Company's Articles of Association, the Board of Directors is required to prepare a balance sheet and a profit and loss statement as of the end of the Company's fiscal year. These financial statements must be presented to the shareholders at the Annual General Meeting for approval, and must be audited by the external auditor prior to submission to the shareholders' meeting.

The Company has prepared the financial statements for the fiscal year ended December 31, 2024, the details of which are provided in Section 3: Financial Statements of the Annual Report (Form 56-1 One Report), which has been distributed to all shareholders. The key highlights are summarized as follows:

(Unit: Million Baht)

Items	Consolidated Financial Statements	Separate Financial Statements	
	2024 (Proposed Year)	2024 (Proposed Year)	2023
Total Assets	607.59	605.75	293.02
Total Liabilities	68.44	68.40	57.20
Shareholders' Equity	539.15	537.35	235.82
Paid-up Capital	300.00	300.00	220.00
Total Revenue	337.59	337.59	245.39
Net Profit	50.16	50.32	32.14
Basic Earnings Per Share (Baht/Share)	0.09	0.09	0.07

The Company's financial statements for the year ended December 31, 2024, have been audited and certified by the Company's auditor, Dr.Virach & Associates Office Co., Ltd. The financial statements have also been reviewed by the Audit Committee and approved by the Board of Directors' meeting held on February 26, 2025.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the financial statements for the year ended 31 December 2024.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the financial statements for the year ended 31 December 2024, with the following voting results:

Approve	440,810,200	votes	or	99.9992%
Disapprove	0	votes	or	0.0000%
Abstain	3,700	votes		

Remark: In this agenda item, 1 additional shareholders joined the meeting, resulting in a total of 43 shareholders attending the meeting and eligible to vote prior to the resolution on this agenda item, representing a total of 440,813,900 shares.

Agenda 5 **To consider and approve the allocation of the net profit as a legal reserve and dividend payment**

The Chairman informed the meeting that, in accordance with Section 116 of the Public Limited Companies Act and Article 50 of the Company's Articles of Association, the Company is required to allocate a portion of its annual net profit as a legal reserve of not less than five percent (5%) of the net profit for the year, after deducting accumulated losses brought forward (if any), until the legal reserve reaches not less than ten percent (10%) of the registered capital.

The Company also has a dividend payment policy of paying no less than forty percent (40%) of the net profit based on the separate financial statements, after deducting corporate income tax and legal reserve allocations. However, the Company may consider paying dividends at a different rate from the stated policy, depending on its operating performance, financial position, liquidity, working capital requirements, business expansion plans, and overall economic conditions.

Based on the Company's operating results, it is proposed that the 2025 Annual General Meeting of Shareholders consider and approve the appropriation of 2.54 million Baht from the net profit for the year 2024 as a legal reserve, which, when combined with the previously allocated reserve of 11.00 million Baht, complies with the statutory requirement. It is also proposed that the meeting approve the payment of a dividend for the year 2024 at the rate of 0.05 Baht per share, totaling 30.00 million Baht, which represents 59.62% of the net profit according to the Company's separate financial statements. This is in line with the Company's dividend policy as mentioned above. The Company has set the Record Date for shareholders entitled to receive dividends as May 7, 2025, and the dividend payment date as May 28, 2025.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the allocation of the net profit as a legal reserve and dividend payment.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the allocation of the net profit as a legal reserve and dividend payment as follows:

(1) Approved the allocation of net profit as a legal reserve for the year 2024, in the amount of 2,540,000 Baht, which is not less than 5% of the Company's net profit.

(2) Approved the dividend payment for the 2024 operating results at a rate of 0.05 Baht per share, totaling 30,000,000 Baht.

with the following voting results:

Approve	440,813,900	votes	or	100.0000%
Disapprove	0	votes	or	0.0000%

Abstain

0 votes

Agenda 6 **To consider and approve the appointment of directors in replacement of those who must retire by rotation**

For this agenda item, in order to ensure that the consideration process is conducted with integrity, fairness, and comply with the principles of good corporate governance practices, the three directors whose terms are expiring, namely: 1. Mr.Vichate Tantiwanich 2. Mr.Jedsada Chokdamsongsuk and 3. Mr.Zongze Wu, who are deemed to have a conflict of interest in this matter, were requested to leave the meeting temporarily until the consideration of this agenda item was concluded.

The Chairman informed the meeting that, in accordance with Section 71 of the Public Limited Companies Act and Article 18 of the Company's Articles of Association, it is stipulated that at every Annual General Meeting of shareholders, one-third (1/3) of the directors must retire from office. If the number of directors cannot be evenly divided into three parts, then the number closest to one-third shall retire. For the first and second years after company registration, the directors to retire shall be selected by drawing lots. In subsequent years, the directors who have been in office the longest shall retire. A retiring director may be re-elected to resume office. Currently, the Company has a total of 11 directors, and at the 2025 Annual General Meeting of Shareholders, 3 directors are due to retire by rotation, as follows:

- | | | |
|---------------|----------------|--|
| 1. Mr.Vichate | Tantiwanich | (Independent Director / Chairman of the Audit Committee) |
| 2. Mr.Jedsada | Chokdamsongsuk | (Independent Director / Audit Committee) |
| 3. Mr.Zongze | Wu | (Director) |

The Board of Directors, excluding those with a conflict of interest, has resolved to propose to the 2025 Annual General Meeting of Shareholders to re-elect all three directors retiring by rotation to resume their positions for another term. The Company has attached the brief profiles of the nominated individuals together with the Notice of the Shareholders' Meeting for shareholders' consideration.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the appointment of directors in replacement of those who must retire by rotation.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the election of 3 directors to replace those who retired by rotation, with the following voting results:

- | | |
|------------------------------|--|
| 1. Mr.Vichate Tantiwanich | (Independent Director / Chairman of the Audit Committee) |
| Approve | 440,711,900 votes or 99.9769% |
| Disapprove | 0 votes or 0.0000% |
| Abstain | 102,000 votes |
| 2. Mr.Jedsada Chokdamsongsuk | (Independent Director / Audit Committee) |
| Approve | 440,813,900 votes or 100.0000% |
| Disapprove | 0 votes or 0.0000% |
| Abstain | 0 votes |
| 3. Mr.Zongze Wu | (Director) |

Approve	440,810,200	votes	or	99.9992%
Disapprove	0	votes	or	0.0000%
Abstain	3,700	votes		

Agenda 7 **To consider and approve the directors' remuneration for the year 2025**

The Chairman informed the meeting that, in accordance with Section 90 of the Public Limited Companies Act, the payment of directors' remuneration shall comply with the Company's Articles of Association and must be approved by a resolution of the shareholders' meeting, passed by no less than two-thirds (2/3) of the total votes of shareholders attending the meeting. Furthermore, Article 33 of the Company's Articles of Association states that directors are entitled to receive remuneration from the Company in the form of honorariums, meeting allowances, gratuities, bonuses, or other benefits, as specified by the Articles or as resolved by the shareholders' meeting. Such remuneration may be set as a fixed amount or based on defined criteria and may be determined either as a one-time arrangement or to remain in effect until further changes are made. In addition, directors are entitled to allowances and benefits according to the Company's internal policies.

The Board of Directors, after careful consideration by the Executive Committee, has evaluated the principles for determining the remuneration of the Company's directors by scrutinizing the appropriateness of the remuneration to be in the same way as listed companies in the same industry as well as considering the operating results, business size, responsibilities of the Board of Directors and the Company's net profit. Therefore, it is deemed appropriate to propose maintaining the director compensation at the same level as in 2024, as detailed below:

Monthly Remuneration of the Board of Directors (Baht/person)

Position	2025	2024	Change from 2024
Chairman of the Board	50,000 Baht	50,000 Baht	-
Directors	40,000 Baht	40,000 Baht	-

Meeting Allowance for Sub-committees. (Audit Committee and Executive Committee)

(Baht/person)

Position	2025	2024	Change from 2024
Chairman of the Board	20,000 Baht	20,000 Baht	-
Directors	15,000 Baht	15,000 Baht	-

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors. (Chief Executive Officer and Deputy Chief Executive Officer)

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the directors' remuneration for the year 2025.

Meeting Resolution The meeting, by not less than two-thirds of the total number of votes of the shareholders present at the meeting, approved the directors' remuneration for the year 2025, with the following voting results:

Approve	440,813,900	votes	or	100.0000%
Disapprove	0	votes	or	0.0000%

Abstain

0 votes

Agenda 8 **To consider and approve the payment of bonuses to the executive directors for the year 2024**

The Chairman informed the meeting that, in accordance with Section 90 of the Public Limited Companies Act, the payment of directors' remuneration shall comply with the Company's Articles of Association and must be approved by a resolution of the shareholders' meeting, passed by no less than two-thirds (2/3) of the total votes of shareholders attending the meeting. Furthermore, Article 33 of the Company's Articles of Association states that directors are entitled to receive remuneration from the Company in the form of honorariums, meeting allowances, gratuities, bonuses, or other benefits, as specified by the Articles or as resolved by the shareholders' meeting. Such remuneration may be set as a fixed amount or based on defined criteria and may be determined either as a one-time arrangement or to remain in effect until further changes are made. In addition, directors are entitled to allowances and benefits according to the Company's internal policies.

The Chairman and the Board of Directors have reviewed the Company's operating performance, business size, and net profit, which are the results of the effective management and leadership of the Executive Directors. As a result, it is deemed appropriate to propose that the meeting consider the payment of a bonus to the Executive Directors for the Company's performance in the year 2024, at the rate of 5% of net profit, amounting to 2,500,000 Baht.

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors. (Chief Executive Officer and Deputy Chief Executive Officer)

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the payment of bonuses to the executive directors for the year 2024.

Meeting Resolution The meeting, by not less than two-thirds of the total number of votes of the shareholders present at the meeting, approved the payment of bonuses to the Executive Committee for the 2024 operating results, at a rate of 5% of the net profit, amounting to 2,500,000 Baht, with the following voting results:

Approve	440,813,900	votes	or	100.0000%
Disapprove	0	votes	or	0.0000%
Abstain	0	votes		

Agenda 9 **To consider and approve the appointment of auditor and fix his/her remuneration for the year 2025**

The Chairman informed the meeting that, in accordance with Section 120 of the Public Limited Companies Act B.E. 2535 (1992) and Articles 58 and 59 of the Company's Articles of Association, the Annual General Meeting of Shareholders is required to appoint the Company's auditor and determine the audit fee each year.

Thus, the 2025 Annual General Meeting of Shareholders of the Company is required to appoint the auditor and determine the auditors' fee for the year 2025. In selecting a qualified auditor with reasonable audit fees for the fiscal year 2025, the Audit Committee has recommended that the 2025 Annual General Meeting of Shareholders appoint an auditor from Dr. Virach & Associates Office Co., Ltd. as the Company's auditors for the year 2025. The proposed auditors are as follows:

- | | |
|---------------------------------|--|
| 1. Dr. Virach Aphimeteetamrong | Certified Public Accountant No. 1378 and/or |
| 2. Mr. Chaiyakorn Aunpitipongsa | Certified Public Accountant No. 3196, and/or |
| 3. Mr. Apiruk Ati-anuwat | Certified Public Accountant No. 5202 |

The audit fee for the Company for the fiscal year 2025 is proposed to be set at 1,830,000 Baht, excluding other expenses, which represents an increase of 190,000 Baht from the fee for the year 2024. This adjustment is due to the Company's investments in subsidiaries and associates, resulting in an increased audit workload for the annual consolidated financial statements and the quarterly consolidated financial statements. Therefore, the audit fee for 2025 has been adjusted accordingly.

All three nominated auditors possess the qualifications required under the notification of the Securities and Exchange Commission (SEC) regarding auditor rotation. Specifically, none of the proposed auditors has performed audit or review services and expressed opinions on the Company's financial statements for five consecutive fiscal years.

Additionally, Dr. Virach & Associates Office Co., Ltd., and the nominated auditors have no relationship or conflict of interest with the Company, its executives, major shareholders, or any related persons.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the appointment of auditor and fix his/her remuneration for the year 2025.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the appointment of auditor and fix his/her remuneration for the year 2025, with the following voting results:

Approve	440,813,900	votes	or	100.0000%
Disapprove	0	votes	or	0.0000%
Abstain	0	votes		

Agenda 10 Others (if any)

The Chairman informed the meeting that, according to Section 105 of the Public Limited Companies Act B.E. 2535 (1992), it is stated that "Shareholders holding not less than one-third (1/3) of the total number of issued shares may request the meeting to consider other matters in addition to those specified in the notice of the meeting."

As no shareholders proposed any additional agenda items, there would be no additional matters presented for the meeting's consideration, and no resolution would be made under this agenda.

The Chairman then opened the session for shareholders to ask questions or comments.

On this matter, shareholders raised several questions and provided comments, which can be summarized as follows:

Question 4

Mr.Torpong Krongtraiwetch (Shareholder): What is the Company's research and development (R&D) budget for 2025?

Answer 4

Mr.Kittikun Rodrangnok: For 2025, the Company has set an R&D budget of around 40 million Baht. The main focus will be on investing in advanced medical technologies, focusing on investment in Advanced Therapy Medicinal Products (ATMP), which covers the development of technologies related to cell therapy, gene therapy, and tissue engineering, which will help the Company strengthen its ability to develop medical innovations and stay competitive globally.

Question 5

Mr.Ekachai Thai-arporn (Shareholder): Regarding the increase in trade receivables to 56 million Baht, how does this increase affect the company's risk, especially in terms of retail receivables?

Answer 5

Mr.Kittikun Rodrangnok: The increase in trade receivables at the end of 2024 was mainly due to the Company's sales growth, particularly in the fourth quarter of the year. During that period, the Company expanded both its services and product sales to private hospitals and government agencies, which led to a significant rise in outstanding receivables. However, the Company has managed credit risk effectively. This can be seen from the improved debt collection rate and the reversal of credit losses that were previously recorded as expenses in 2023, some of which were recognized as income in 2024. This reflects tight control over receivables and a provision for bad debts that accurately matches the actual risk level of each customer.

The Chief Executive Officer expressed appreciation to all shareholders, proxy holders, representatives from the Thai Investors Association, and all relevant parties for taking the time to attend the meeting. She assured all shareholders that the Company is well-prepared, with concrete business plans in place, and is committed to ensuring long-term stability, sustainability, and continued growth in line with the Company's strategic direction, both in terms of business performance and the advancement of Thailand's public health sector.

The Chairman of the meeting then thanked all shareholders for their attendance and formally declared the meeting closed.

The Meeting was adjourned at 12:00 hours.

- *Signature* -

Dr. Thosaporn Sirisumphand

Chairman of the meeting

Attachment

Summary of Questions, Answers, and Suggestions from the 2025 Annual General Meeting of Shareholders

Agenda 10 **Others (if any)**

Question 6

Ms.Patcharin Kulmoranon (Shareholder): With the growing trend of people aiming to live a long and healthy life up to 120 years, how is the Company benefiting from this movement, and does it have plans to expand additional services in the future?

Answer 6

Dr.Saowalak Dansakul: The public's growing interest in achieving the goal of living a long and healthy life up to 120 years is a significant driving force that positively impacts the Company, particularly in terms of encouraging understanding and interest in personalized, in-depth healthcare, which is fundamentally based on genetic analysis and individual biological data.

As more people begin to recognize that “longevity” requires early planning and prevention such as genetic testing to assess long-term disease risk, analysis of personal health behaviors and indicators (Personal Health Index), and proactive health management, these factors contribute directly to the growth of the genetic services currently offered by the Company.

In the next phase, the continued expansion of this trend will create new opportunities for the Company in both the development of new services that address deeper health concerns and the further enhancement of genetic testing technologies for broader and more precise application, supported by the Company's accumulated knowledge, ongoing research, and continuously developed database.

The Company is also closely monitoring government efforts to support and promote health innovation, particularly through the “Health Sandbox” initiative, which includes technologies such as cell therapy and stem cell treatment. These approaches offer new avenues for in-depth health restoration and delaying physical degeneration at the cellular level. The introduction of innovation sandbox environments not only reduces regulatory barriers but also presents a valuable opportunity for the Company to participate in the development of new technologies while adhering to safety and ethical standards under the oversight of relevant authorities.

With its strong technological infrastructure and a team of experienced professionals, the Company is well-positioned to respond to these emerging trends and to grow in tandem with increasing demand for in-depth, personalized health care across all stages of life.

Question 7

Mr.Torpong Krongtraiwed (Shareholder) raised the following additional questions:

1. In 2025, which products are expected to drive revenue growth, and what strategies will the Company use?
2. What is the current value of the Company's backlog, particularly from equipment sales and bidding projects, and when does the Company expect to recognize revenue from these projects?
3. In 2025, how much does the Company plan to bid for in new projects, and what are the chances of winning those contracts?
4. What are the reasons for the increase in the number of tier 2 and 3 receivables and the increase in bad debt provisions? How does the Company assess the collectability of these debts?
5. Over the next three years, what growth opportunities and key challenges does the Company foresee?

Answer 7

Mr.Kittikun Rodrangnok:

1. In 2025, revenue growth is expected to come mainly from the sales of laboratory devices and equipment, which are currently core products offered by the Company, particularly those involving

integrated solutions and advanced technologies like Next Generation Sequencing (NGS) systems, which continue to show steady growth.

The Company's revenue strategy focuses on expanding its customer base to include both public and private sectors, improving operational efficiency, and developing innovative products and services that meet evolving market needs. The Company also aims to stay aligned with rapid changes in the healthcare and medical technology industries.

2. At present, the Company's backlog is at a satisfactory level and includes ongoing product sales projects and ongoing bidding. Revenue from these projects will be recognized gradually based on project progress and delivery timelines, with most of it expected to be recognized starting in 2025.
3. In 2025, the Company is considering bidding for several potential and interesting projects. The total value of these projects may vary depending on the type of work and the project owner. The Company's chances of winning depend on the specific conditions of each project and the level of competition at the time.
4. The increase in Tier 2 and Tier 3 receivables in 2024 was mainly due to a growing number of government clients. Typically, payment and disbursement processes in the public sector take longer than in the private sector, resulting in some receivables remaining unpaid beyond their expected due dates. However, the Company closely monitors debtor status and believes that these receivables are still collectible at a reasonable level. Additional risk management measures have been implemented to ensure that the situation does not negatively affect cash flow or overall financial performance.
5. Over the next three years, the Company sees growth opportunities in expanding markets related to advanced medical technologies, comprehensive laboratory services, and collaborations between public and private sectors in laboratory operations. The Company is well-prepared to meet these demands.

At the same time, key challenges include fluctuating raw material costs, intense competition within the industry, and economic uncertainties. To mitigate these risks, the Company has developed risk management plans and aims to develop the organization to be flexible and sustainable in competition.

Question 8

Ms.Patcharin Kulmoranon (Shareholder): Please explain the term "ATMP" that the company is currently conducting research and development (R&D).

Answer 8

Mr.Xiaohan Wang: Advanced Therapeutic and Medicinal Products (ATMPs) refer to advanced medical products, such as cell therapy and gene therapy, which have been developed for use in the treatment of certain types of cancer, as well as complex genetic diseases. The Company is currently conducting feasibility studies to develop products in this group in collaboration with both domestic and international researchers to enhance the country's medical innovation capabilities. Diseases included in the research and development plan include lymphoma, bone marrow cancer, and certain genetic diseases, all of which require specific and highly accurate treatment approaches.

Question 9

Mr.Papinwich Anantasetthakul (Shareholder): How does the current problematic NIPT testing under the National Health Security Office (NHSO) affected the Company?

Answer 9

Dr.Saowalak Dansakul: Although the implementation of the non-invasive prenatal testing (NIPT) program under the NHSO benefits scheme is still under review and no official guidelines have been announced, the Company views this development as a positive signal for both the industry and the Company, particularly in terms of public awareness of genetic testing technologies, especially those using Next-Generation Sequencing (NGS). The growing public interest and awareness clearly highlight the importance of prenatal genetic screening, helping to promote broader understanding and appreciation of the value and benefits of genetic technologies in healthcare.